Skip to main content

Table 4 Base case results

From: Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

 

Current scenario tested

No-testing

Difference

Cost of testing

€ 3,613,701

€ 0

€ + 3, 613, 701

Cost of treatment

€ 854,664,411

€ 806,959,058

€ + 47, 705, 353

Total costs

€ 858,278,111

€ 806,959,058

€ + 51, 319, 053

LY

21.233,59

16.173,45

+ 5060.14

QALYs

14.654,68

10.748,05

+ 3906.64

ICER (€/LY gained)

€ 10,142/LY

ICUR (€/QALY gained)

€ 13,136/QALY

  1. LY life years, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio